Health Economics›Merkel cell carcinoma›Metastatic or advanced disease first-line therapy

Metastatic or advanced disease first-line therapy

Merkel cell carcinoma · 2 regimens

Cost estimates only — modelled on a typical patient (BSA 1.7 m², 70 kg, CrCl 90 mL/min) using the cheapest available formulary presentation. Excludes vial wastage, facility fees, supportive care, and infusion consumables. Not for billing, formulary decisions, or clinical use.

Filters

Y-axis

Cost vs Efficacy · 1 point

Fully pricedPartial pricing

Regimen	Biomarker	Cost/cycle ↓	Cycle	PFS ↕	OS ↕	Est. cycles	Course cost ↕	Evidence
Pembrolizumab monotherapy Variant #01	—	R 286 955	14d	~5.3 mo	~32.7 mo	~12	~R 3 443 463 PFS proxy · indirect	12
Retifanlimab monotherapy Variant #01 Partial	—	—	28d	—	—	—	—	—

2 of 2 regimens shown